- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
DNMT3A Antibody / DNA (cytosine-5)-methyltransferase 3A (FY13240)
Email: info@nsjbio.com
| Catalog No | Formulation | Size | Price (USD) | ||
|---|---|---|---|---|---|
|
FY13240 | Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml | 100 ug | 439 |
Related Products
|
DNMT3A antibody detects DNA (cytosine-5)-methyltransferase 3A, an enzyme responsible for establishing de novo DNA methylation patterns during development and differentiation. The UniProt recommended name is DNA (cytosine-5)-methyltransferase 3A (DNMT3A). This nuclear enzyme catalyzes the transfer of a methyl group to the 5-position of cytosine residues within CpG dinucleotides, a key mechanism of epigenetic gene regulation.
Functionally, DNMT3A antibody identifies an 912-amino-acid methyltransferase that functions together with DNMT3B and DNMT3L to establish DNA methylation marks during embryogenesis. DNMT3A binds chromatin through its PWWP domain and ADD (ATRX-DNMT3-DNMT3L) domain, recognizing histone modifications that guide locus-specific methylation. By controlling methylation of promoters, enhancers, and repetitive elements, DNMT3A ensures stable gene silencing and genome integrity.
The DNMT3A gene is located on chromosome 2p23.3 and is highly expressed in stem cells, germ cells, and hematopoietic progenitors. Expression decreases during differentiation, consistent with its role in developmental programming. DNMT3A activity is essential for imprinting, X-chromosome inactivation, and transposon silencing.
Pathologically, mutations in DNMT3A are among the most common in acute myeloid leukemia (AML), myelodysplastic syndromes, and clonal hematopoiesis. Loss-of-function mutations impair methylation fidelity, causing epigenetic instability and aberrant gene expression. Germline mutations lead to Tatton-Brown-Rahman syndrome, characterized by overgrowth and intellectual disability. Research using DNMT3A antibody supports studies in epigenetics, cancer biology, and developmental regulation.
DNMT3A antibody is validated for western blotting, immunofluorescence, and chromatin immunoprecipitation to detect DNA methyltransferases. NSJ Bioreagents provides DNMT3A antibody reagents optimized for studies in epigenetic modification, chromatin remodeling, and transcriptional silencing.
Structurally, DNA (cytosine-5)-methyltransferase 3A consists of an N-terminal regulatory region containing the PWWP and ADD domains, and a C-terminal catalytic domain with the conserved PCQ motif required for methyl group transfer. DNMT3A forms complexes with DNMT3L to enhance DNA binding and catalytic efficiency. This antibody enables investigation of DNMT3As function in epigenetic gene silencing and oncogenic transformation.
Optimal dilution of the DNMT3A antibody should be determined by the researcher.
E.coli-derived human DNMT3A recombinant protein (Position: M1-Y284) was used as the immunogen for the DNMT3A antibody.
After reconstitution, the DNMT3A antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.
Powered by Bioz